CLD 202
Alternative Names: CLD-202Latest Information Update: 05 Dec 2023
At a glance
- Originator Calidi Biotherapeutics
- Class Antineoplastics; Immunotherapies; Mesenchymal stem cell therapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours